Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Over a million patients benefit from their therapies every year.
Award
- Nominated in 2019
- Winner in 2020